‘Soliris,’ a PNH treatment, applied by ‘Refund RSA’ next month
The only PNH(paroxysmal nocturnal hemoglobinuria) treatment, ‘Soliris,’ will be applied by RSA from October.
According to the industry concerned on the 18th, Soliris(eculizumab), which will face the ending of its refund demo project in the coming 30th, was confirmed to change to the RSA(Risk Sha...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
